Home / Neuroonkologie / ESMO 2019: Welche Gliom-Gruppe könnte Benefit von Immuntherapie haben?

|

Ass.-Prof. PD Dr. Anna-Sophie Berghoff

ESMO 2019: Welche Gliom-Gruppe könnte Benefit von Immuntherapie haben?

Ass.-Prof. PD. Dr. Anna Berghoff, Leiterin Translational Research Unit, Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Wien, spricht über die besondere Bedeutung von Phase-0-Studien in der Neuro-Onkologie, sowie die Rolle der Immunonkologie bei Gliomen.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten
Prof. Berghoff bespricht folgende Abstracts:
  • Sanai N et al. A phase 0/II clinical trial of a CDK4/6 inhibitor in aggressive meningioma patients. #392O
  • Kamiya-Matsuoka C et al. Is immuno-oncology therapy effective in hypermutator glioblastoma with somatic or germline mutations? #393O
  • Mair M et al. Circulating PD-L1 levels vary across brain tumour entities and are oppositely linked to survival in glioblastoma and lower grade glioma patients. #395PD
  • Mir Seyed Nazari P et al. Association of systemic inflammation with local tumour characteristics and survival in glioma patients. #399PD
  • Multidisciplinary session: WHO grade II and III gliomas: State of the art management
Pressemeldungen Nivolumab im Glioblastom:

Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme [press release]. Princeton, NJ: Bristol-Myers Squibb Company; May 9, 2019. Accessed September 27, 2019.

Bristol-Myers Squibb Provides Update on Phase 3 Opdivo(nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme [press release]. Princeton, NJ: Bristol-Myers Squibb Company; September 5, 2019. Accessed September 27, 2019.

Quelle

ESMO 2019 Congress

LOGIN